In this Research Topic, we hosted eight in-depth reviews, minireviews, and original research articles on the biological and clinical aspects of HLA-G. This could be unattainable without the enthusiastic involvement of all contributing authors, participating reviewers and the assistance from the staff of Frontiers in Immunology.HLA-G belongs to the non-classical HLA class I family. HLA-G features limited genetic variation, very restricted tissue expression, and immune tolerogenic functions, being a ligand of immune inhibitory receptors. HLA-G is now recognized as an important immune checkpoint.
HLA-G1~HLA-G4; soluble isoforms:HLA-G5~HLA-G7), can be generated due to its primary transcript alternative splicing. Since HLA-G gene had been identified in 1987 (1) and HLA-G protein expression first observed in extravillious cytotrophoblasts in 1990 (2) In summary, this special issue highlights the current advances regarding the biological and clinical importance of HLA-G in various physio-phatological situations. Undoubtedly, HLA-G is a promising biomarker and therapeutic target for different diseases, even though isoform-specific antibodies are still lacking, which prevents advances in characterizing their clinical significance.
YWH wrote the first draft of the manuscript and updated the last version.JLM corrected the draft.

